424 related articles for article (PubMed ID: 33106286)
1. Brodalumab in psoriatic arthritis: results from the randomised phase III AMVISION-1 and AMVISION-2 trials.
Mease PJ; Helliwell PS; Hjuler KF; Raymond K; McInnes I
Ann Rheum Dis; 2021 Feb; 80(2):185-193. PubMed ID: 33106286
[TBL] [Abstract][Full Text] [Related]
2. Brodalumab, a human anti-interleukin-17-receptor antibody in the treatment of Japanese patients with moderate-to-severe plaque psoriasis: Efficacy and safety results from a phase II randomized controlled study.
Nakagawa H; Niiro H; Ootaki K;
J Dermatol Sci; 2016 Jan; 81(1):44-52. PubMed ID: 26547109
[TBL] [Abstract][Full Text] [Related]
3. Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNFα inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trial.
Deodhar A; Helliwell PS; Boehncke WH; Kollmeier AP; Hsia EC; Subramanian RA; Xu XL; Sheng S; Agarwal P; Zhou B; Zhuang Y; Ritchlin CT;
Lancet; 2020 Apr; 395(10230):1115-1125. PubMed ID: 32178765
[TBL] [Abstract][Full Text] [Related]
4. Brodalumab, an anti-IL17RA monoclonal antibody, in psoriatic arthritis.
Mease PJ; Genovese MC; Greenwald MW; Ritchlin CT; Beaulieu AD; Deodhar A; Newmark R; Feng J; Erondu N; Nirula A
N Engl J Med; 2014 Jun; 370(24):2295-306. PubMed ID: 24918373
[TBL] [Abstract][Full Text] [Related]
5. Long-Term Efficacy and Safety of Guselkumab, a Monoclonal Antibody Specific to the p19 Subunit of Interleukin-23, Through Two Years: Results From a Phase III, Randomized, Double-Blind, Placebo-Controlled Study Conducted in Biologic-Naive Patients With Active Psoriatic Arthritis.
McInnes IB; Rahman P; Gottlieb AB; Hsia EC; Kollmeier AP; Xu XL; Jiang Y; Sheng S; Shawi M; Chakravarty SD; van der Heijde D; Mease PJ
Arthritis Rheumatol; 2022 Mar; 74(3):475-485. PubMed ID: 34719872
[TBL] [Abstract][Full Text] [Related]
6. Impact of guselkumab, an interleukin-23 p19 subunit inhibitor, on enthesitis and dactylitis in patients with moderate to severe psoriatic arthritis: results from a randomised, placebo-controlled, phase II study.
Mease PJ; Gladman DD; Deodhar A; McGonagle DG; Nash P; Boehncke WH; Gottlieb A; Xu XL; Xu S; Hsia EC; Karyekar CS; Helliwell PS
RMD Open; 2020 Jul; 6(2):. PubMed ID: 32665433
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of guselkumab in patients with active psoriatic arthritis: a randomised, double-blind, placebo-controlled, phase 2 study.
Deodhar A; Gottlieb AB; Boehncke WH; Dong B; Wang Y; Zhuang Y; Barchuk W; Xu XL; Hsia EC;
Lancet; 2018 Jun; 391(10136):2213-2224. PubMed ID: 29893222
[TBL] [Abstract][Full Text] [Related]
8. Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a Phase 3 double-blind randomised placebo-controlled study (RAPID-PsA).
Mease PJ; Fleischmann R; Deodhar AA; Wollenhaupt J; Khraishi M; Kielar D; Woltering F; Stach C; Hoepken B; Arledge T; van der Heijde D
Ann Rheum Dis; 2014 Jan; 73(1):48-55. PubMed ID: 23942868
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of ustekinumab in biologic-naïve patients with psoriatic arthritis by prior treatment exposure and disease duration: data from PSUMMIT 1 and PSUMMIT 2.
McInnes IB; Chakravarty SD; Apaolaza I; Kafka S; Hsia EC; You Y; Kavanaugh A
RMD Open; 2019; 5(2):e000990. PubMed ID: 31565242
[TBL] [Abstract][Full Text] [Related]
10. Secukinumab improves active psoriatic arthritis symptoms and inhibits radiographic progression: primary results from the randomised, double-blind, phase III FUTURE 5 study.
Mease P; van der Heijde D; Landewé R; Mpofu S; Rahman P; Tahir H; Singhal A; Boettcher E; Navarra S; Meiser K; Readie A; Pricop L; Abrams K
Ann Rheum Dis; 2018 Jun; 77(6):890-897. PubMed ID: 29550766
[TBL] [Abstract][Full Text] [Related]
11. Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial.
Mease PJ; Rahman P; Gottlieb AB; Kollmeier AP; Hsia EC; Xu XL; Sheng S; Agarwal P; Zhou B; Zhuang Y; van der Heijde D; McInnes IB;
Lancet; 2020 Apr; 395(10230):1126-1136. PubMed ID: 32178766
[TBL] [Abstract][Full Text] [Related]
12. Improvement in Psoriasis Signs and Symptoms Assessed by the Psoriasis Symptom Inventory with Brodalumab Treatment in Patients with Psoriatic Arthritis.
Mease PJ; Genovese MC; Mutebi A; Viswanathan HN; Chau D; Feng J; Erondu N; Nirula A
J Rheumatol; 2016 Feb; 43(2):343-9. PubMed ID: 26773108
[TBL] [Abstract][Full Text] [Related]
13. Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis.
Lebwohl M; Strober B; Menter A; Gordon K; Weglowska J; Puig L; Papp K; Spelman L; Toth D; Kerdel F; Armstrong AW; Stingl G; Kimball AB; Bachelez H; Wu JJ; Crowley J; Langley RG; Blicharski T; Paul C; Lacour JP; Tyring S; Kircik L; Chimenti S; Callis Duffin K; Bagel J; Koo J; Aras G; Li J; Song W; Milmont CE; Shi Y; Erondu N; Klekotka P; Kotzin B; Nirula A
N Engl J Med; 2015 Oct; 373(14):1318-28. PubMed ID: 26422722
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of tildrakizumab in patients with active psoriatic arthritis: results of a randomised, double-blind, placebo-controlled, multiple-dose, 52-week phase IIb study.
Mease PJ; Chohan S; Fructuoso FJG; Luggen ME; Rahman P; Raychaudhuri SP; Chou RC; Mendelsohn AM; Rozzo SJ; Gottlieb A
Ann Rheum Dis; 2021 Sep; 80(9):1147-1157. PubMed ID: 33985942
[TBL] [Abstract][Full Text] [Related]
15. Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1.
Mease PJ; van der Heijde D; Ritchlin CT; Okada M; Cuchacovich RS; Shuler CL; Lin CY; Braun DK; Lee CH; Gladman DD;
Ann Rheum Dis; 2017 Jan; 76(1):79-87. PubMed ID: 27553214
[TBL] [Abstract][Full Text] [Related]
16. Bimekizumab in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor-α inhibitors: a randomised, double-blind, placebo-controlled, phase 3 trial (BE COMPLETE).
Merola JF; Landewé R; McInnes IB; Mease PJ; Ritchlin CT; Tanaka Y; Asahina A; Behrens F; Gladman DD; Gossec L; Gottlieb AB; Thaçi D; Warren RB; Ink B; Assudani D; Bajracharya R; Shende V; Coarse J; Coates LC
Lancet; 2023 Jan; 401(10370):38-48. PubMed ID: 36495881
[TBL] [Abstract][Full Text] [Related]
17. A study to evaluate the safety, tolerability, and efficacy of brodalumab in subjects with rheumatoid arthritis and an inadequate response to methotrexate.
Pavelka K; Chon Y; Newmark R; Lin SL; Baumgartner S; Erondu N
J Rheumatol; 2015 Jun; 42(6):912-9. PubMed ID: 25877498
[TBL] [Abstract][Full Text] [Related]
18. The Efficacy and Safety of Clazakizumab, an Anti-Interleukin-6 Monoclonal Antibody, in a Phase IIb Study of Adults With Active Psoriatic Arthritis.
Mease PJ; Gottlieb AB; Berman A; Drescher E; Xing J; Wong R; Banerjee S
Arthritis Rheumatol; 2016 Sep; 68(9):2163-73. PubMed ID: 27059799
[TBL] [Abstract][Full Text] [Related]
19. A phase Ib multiple ascending dose study evaluating safety, pharmacokinetics, and early clinical response of brodalumab, a human anti-IL-17R antibody, in methotrexate-resistant rheumatoid arthritis.
Martin DA; Churchill M; Flores-Suarez L; Cardiel MH; Wallace D; Martin R; Phillips K; Kaine JL; Dong H; Salinger D; Stevens E; Russell CB; Chung JB
Arthritis Res Ther; 2013 Oct; 15(5):R164. PubMed ID: 24286136
[TBL] [Abstract][Full Text] [Related]
20. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT).
Antoni CE; Kavanaugh A; Kirkham B; Tutuncu Z; Burmester GR; Schneider U; Furst DE; Molitor J; Keystone E; Gladman D; Manger B; Wassenberg S; Weier R; Wallace DJ; Weisman MH; Kalden JR; Smolen J
Arthritis Rheum; 2005 Apr; 52(4):1227-36. PubMed ID: 15818699
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
